FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590062885> ?p ?o ?g. }

• W2590062885 endingPage "593" @default.
• W2590062885 startingPage "593" @default.
• W2590062885 abstract "593 Background: Inhibition of the EGFR pathway has become a key part in the treatment of colorectal cancer. There were few studies for clinical early predictive markers. To investigate the early magnesium (Mg 2+ ), calcium (Ca 2+ ), albumin (Alb), CEA and CA 19-9 plasma level reductions as a predictor for clinical outcome in terms of progression free survival (PFS) and overall survival (OS). Methods: 200 patients (pts) with mCRC treated by Pmab contained chemotherapy were retrospectively registered from 20 centers in Japan (HGCSG 1002 study). Of these, the pts that were refractory to or intolerant for 5-FU/ irinotecan/ oxaliplatin, and were never administered anti-EGFR-antibody, were included in this analysis. Mg 2+ , Ca 2+ , Alb, CEA and CA19-9 plasma levels were obtained from medical records. The differences in terms of PFS and OS according to the presence of Mg 2+ , Ca 2+ , Alb, CEA and CA19-9 reductions were evaluated by the log-rank test. Results: Of 67 pts were able to evaluate for this analysis. Pts’ characteristics were as follows: male/female 38/29, median age 64 (range 45-81), ECOG PS (0/1/2- ) 45/17/5. Response rate and disease control rate were 16.4% and 65.7%, PFS and OS were 4.3 m and 12.4 m, respectively. There were no correlations between Ca/Alb plasma level reductions and PFS/OS. Mg 2+ reduction of at least 50% respect to the basal value during the course of treatment was significantly correlated with improved OS and PFS (OS, P=0.03; PFS, P=0.01), but the early reduction (until the 4th week or the 8th week after start of chemotherapy) was not correlated with OS and PFS. An early CEA serum level reduction of at least 40% until the 8th week was significantly correlated with improved OS and PFS (OS, P=0.04; PFS, P=0.07), moreover of at least 30% until the 4th week was correlated to longer PFS (P=0.053). Similar results were seen in CA19-9. Conclusions: An early CEA plasma level reduction of at least 30% or 40% was suggested to be a predictor for PFS in Pmab containing chemotherapy for mCRC pts. Although Mg 2+ serum level reduction was correlated to clinical outcome, but could not show that is an early predictor for PFS and OS in our study." @default.
• W2590062885 created "2017-03-03" @default.
• W2590062885 creator A5013280808 @default.
• W2590062885 creator A5014225991 @default.
• W2590062885 creator A5022036602 @default.
• W2590062885 creator A5022068319 @default.
• W2590062885 creator A5025447515 @default.
• W2590062885 creator A5026656732 @default.
• W2590062885 creator A5026866129 @default.
• W2590062885 creator A5037372375 @default.
• W2590062885 creator A5047037093 @default.
• W2590062885 creator A5048421476 @default.
• W2590062885 creator A5048919337 @default.
• W2590062885 creator A5051241836 @default.
• W2590062885 creator A5051255682 @default.
• W2590062885 creator A5054182211 @default.
• W2590062885 creator A5055464423 @default.
• W2590062885 creator A5057711892 @default.
• W2590062885 creator A5060570178 @default.
• W2590062885 creator A5076203131 @default.
• W2590062885 creator A5076417403 @default.
• W2590062885 creator A5084976321 @default.
• W2590062885 date "2013-02-01" @default.
• W2590062885 modified "2023-10-01" @default.
• W2590062885 title "Retrospective cohort study on the safety and efficacy of panitumumab (Pmab) for patients with metastatic colorectal cancer (mCRC): The HGCSG1002 study—Analysis of clinical early predictor for the efficacy." @default.
• W2590062885 doi "https://doi.org/10.1200/jco.2013.31.4_suppl.593" @default.
• W2590062885 hasPublicationYear "2013" @default.
• W2590062885 type Work @default.
• W2590062885 sameAs 2590062885 @default.
• W2590062885 citedByCount "0" @default.
• W2590062885 crossrefType "journal-article" @default.
• W2590062885 hasAuthorship W2590062885A5013280808 @default.
• W2590062885 hasAuthorship W2590062885A5014225991 @default.
• W2590062885 hasAuthorship W2590062885A5022036602 @default.
• W2590062885 hasAuthorship W2590062885A5022068319 @default.
• W2590062885 hasAuthorship W2590062885A5025447515 @default.
• W2590062885 hasAuthorship W2590062885A5026656732 @default.
• W2590062885 hasAuthorship W2590062885A5026866129 @default.
• W2590062885 hasAuthorship W2590062885A5037372375 @default.
• W2590062885 hasAuthorship W2590062885A5047037093 @default.
• W2590062885 hasAuthorship W2590062885A5048421476 @default.
• W2590062885 hasAuthorship W2590062885A5048919337 @default.
• W2590062885 hasAuthorship W2590062885A5051241836 @default.
• W2590062885 hasAuthorship W2590062885A5051255682 @default.
• W2590062885 hasAuthorship W2590062885A5054182211 @default.
• W2590062885 hasAuthorship W2590062885A5055464423 @default.
• W2590062885 hasAuthorship W2590062885A5057711892 @default.
• W2590062885 hasAuthorship W2590062885A5060570178 @default.
• W2590062885 hasAuthorship W2590062885A5076203131 @default.
• W2590062885 hasAuthorship W2590062885A5076417403 @default.
• W2590062885 hasAuthorship W2590062885A5084976321 @default.
• W2590062885 hasConcept C121608353 @default.
• W2590062885 hasConcept C126322002 @default.
• W2590062885 hasConcept C143998085 @default.
• W2590062885 hasConcept C167135981 @default.
• W2590062885 hasConcept C2776694085 @default.
• W2590062885 hasConcept C2778332735 @default.
• W2590062885 hasConcept C2779998722 @default.
• W2590062885 hasConcept C2780259306 @default.
• W2590062885 hasConcept C2780739268 @default.
• W2590062885 hasConcept C2780962732 @default.
• W2590062885 hasConcept C526805850 @default.
• W2590062885 hasConcept C71924100 @default.
• W2590062885 hasConcept C90924648 @default.
• W2590062885 hasConceptScore W2590062885C121608353 @default.
• W2590062885 hasConceptScore W2590062885C126322002 @default.
• W2590062885 hasConceptScore W2590062885C143998085 @default.
• W2590062885 hasConceptScore W2590062885C167135981 @default.
• W2590062885 hasConceptScore W2590062885C2776694085 @default.
• W2590062885 hasConceptScore W2590062885C2778332735 @default.
• W2590062885 hasConceptScore W2590062885C2779998722 @default.
• W2590062885 hasConceptScore W2590062885C2780259306 @default.
• W2590062885 hasConceptScore W2590062885C2780739268 @default.
• W2590062885 hasConceptScore W2590062885C2780962732 @default.
• W2590062885 hasConceptScore W2590062885C526805850 @default.
• W2590062885 hasConceptScore W2590062885C71924100 @default.
• W2590062885 hasConceptScore W2590062885C90924648 @default.
• W2590062885 hasIssue "4_suppl" @default.
• W2590062885 hasLocation W25900628851 @default.
• W2590062885 hasOpenAccess W2590062885 @default.
• W2590062885 hasPrimaryLocation W25900628851 @default.
• W2590062885 hasRelatedWork W1975647291 @default.
• W2590062885 hasRelatedWork W2080692829 @default.
• W2590062885 hasRelatedWork W2545945608 @default.
• W2590062885 hasRelatedWork W2577979650 @default.
• W2590062885 hasRelatedWork W2602241548 @default.
• W2590062885 hasRelatedWork W2617055067 @default.
• W2590062885 hasRelatedWork W3000288349 @default.
• W2590062885 hasRelatedWork W3147937635 @default.
• W2590062885 hasRelatedWork W3177622693 @default.
• W2590062885 hasRelatedWork W349909140 @default.
• W2590062885 hasVolume "31" @default.
• W2590062885 isParatext "false" @default.
• W2590062885 isRetracted "false" @default.
• W2590062885 magId "2590062885" @default.
• W2590062885 workType "article" @default.